Increase Translational Success of CNS Drug Candidates

The overall approval rates of CNS and pain drugs are one of the lowest in the industry. Many factors contribute to the low success rates, such as the complexity of the human brain, the lack of understanding of neurobiological mechanisms, and the difficulty in measuring appropriate clinical endpoints.

In an effort to improve the efficiency of drug development and clinical trials, focus has turned to leveraging translational science through new models, methods and biomarkers. Building connections between early stage researchers and clinicians has also paved the way for novel study designs and endpoints.

This whitepaper provides strategies for strengthening therapeutic programs and case studies that show the successful development of translational models, biomarkers and clinical endpoints.

Complete this form for instant access to the whitepaper.